Wechselwirkung zwischen Perampanel und Ritonavir
Perampanel und Ritonavir: Beide FDA-Fachinformationen versehen diese Kombination mit den stärksten Formulierungen, etwa einer Gegenanzeige, einem umrahmten Warnhinweis (Boxed Warning) oder der Anweisung, sie zu vermeiden.
Nicht ohne ärztliche Anleitung kombinieren. Die unten zitierten Formulierungen der Fachinformation sind die stärksten, die die FDA verwendet.
Was die FDA-Fachinformationen sagen
Aus der FDA-Fachinformation zu Ritonavir (Norvir) · Stand 2026-07-23
WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism…
…POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS See full prescribing information for complete boxed warning Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the…
…Non-opioid Analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine ○ PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension ○ Sedative/Hypnotics: triazolam, orally administered midazolam • NORVIR is contraindicated with drugs that are potent CYP3A inducers where significantly reduced ritonavir plasma concentrations…
Sedative/Hypnotics: triazolam, orally administered midazolam ↑ triazolam ↑ midazolam Contraindicated due to potential for prolonged or increased sedation or respiratory depression [see Contraindications ( 4 ) ] .
Anticonvulsants: carbamazepine, clonazepam, ethosuximide ↑ anticonvulsants A dose decrease may be needed for these drugs when co-administered with ritonavir and therapeutic concentration monitoring is recommended for these anticonvulsants, if available.
Aus der FDA-Fachinformation zu Perampanel (Fycompa) · Stand 2024-01-05
Moderate and Strong CYP3A4 Inducers (including carbamazepine, oxcarbazepine, and phenytoin): increase clearance of perampanel and decrease perampanel plasma concentrations.
When moderate or strong CYP3A4 inducers are introduced or withdrawn, monitor patients closely.
Moderate and Strong CYP3A4 Inducers The concomitant use of known moderate and strong CYP3A4 inducers including carbamazepine, phenytoin, or oxcarbazepine with FYCOMPA decreased the plasma levels of perampanel by approximately 50-67% [see Clinical Pharmacology (12.3) ] .
The starting doses for FYCOMPA should be increased in the presence of moderate or strong CYP3A4 inducers [see Dosage and Administration (2.3) ] .
When these moderate or strong CYP3A4 inducers are introduced or withdrawn from a patient’s treatment regimen, the patient should be closely monitored for clinical response and tolerability.
Sie nehmen mehr als diese beiden ein? Wechselwirkungen summieren sich. Prüfen Sie Ihre gesamte Liste auf einmal; sie bleibt in Ihrem Browser.
Im Wechselwirkungscheck öffnenKeine medizinische Beratung. Interaction Checker zitiert Texte aus FDA-Fachinformationen und NIH-Faktenblättern. Ob eine Wechselwirkung für Sie von Bedeutung ist, hängt von Dosierung, Einnahmezeitpunkt, Nieren- und Leberfunktion und weiteren Erkrankungen ab. Lassen Sie das in der Apotheke oder von Ihrer Ärztin bzw. Ihrem Arzt bestätigen.